Health · 3 views
Immediate evolocumab after a heart attack improves LDL-cholesterol goals but not early cardiovascular outcomes
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not ob…
Story Brief
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care. These were the main findings of the AMUNDSEN trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in JAMA.
Read full article on Medical XpressAI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Digital strategy helps patients with heart failure to receive proven medicationContinue reading
- After TAVI, anticoagulants outperform antiplatelet agents at preventing clotsContinue reading
- Public confidence in one's own health care provider remains highContinue reading
- High fertility costs push Americans abroad for IVF treatmentContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow